What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
George D. Demetri spends much of his time researching Internal medicine, Imatinib mesylate, Cancer research, Surgery and Oncology.
His study focuses on the intersection of Internal medicine and fields such as Gastroenterology with connections in the field of Pharmacokinetics.
His biological study spans a wide range of topics, including GiST and Stromal tumor.
His work deals with themes such as Tyrosine kinase, Receptor tyrosine kinase and Proto-Oncogene Proteins c-kit, which intersect with Cancer research.
His Surgery study integrates concerns from other disciplines, such as Sarcoma and Hazard ratio.
His work in Oncology covers topics such as Cancer which are related to areas like Anemia, Quality of life and Progressive disease.
His most cited work include:
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (3544 citations)
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (1974 citations)
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (1920 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, GiST, Cancer research and Surgery.
His work in Internal medicine addresses issues such as Sarcoma, which are connected to fields such as Leiomyosarcoma.
His biological study deals with issues like Trabectedin, which deal with fields such as Dacarbazine.
His studies in GiST integrate themes in fields like Imatinib, Imatinib mesylate, Stromal tumor, Tyrosine-kinase inhibitor and Sunitinib.
The study incorporates disciplines such as Tyrosine kinase, Cancer, Immunology and Receptor tyrosine kinase in addition to Cancer research.
His research investigates the connection between Surgery and topics such as Gastroenterology that intersect with issues in Pharmacokinetics.
He most often published in these fields:
- Internal medicine (52.91%)
- Oncology (41.10%)
- GiST (30.39%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (52.91%)
- Oncology (41.10%)
- Cancer research (23.94%)
In recent papers he was focusing on the following fields of study:
George D. Demetri mostly deals with Internal medicine, Oncology, Cancer research, Sarcoma and Entrectinib.
His work is dedicated to discovering how Internal medicine, Trabectedin are connected with Ovarian cancer and other disciplines.
His Oncology research includes themes of Clinical trial, Phases of clinical research, Incidence, Medical record and Cohort.
George D. Demetri studies Cancer research, focusing on GiST in particular.
George D. Demetri has researched GiST in several fields, including Enhancer, Regorafenib, Imatinib and Stromal tumor.
His Sarcoma research incorporates elements of Immune checkpoint, Leiomyosarcoma and Immunohistochemistry.
Between 2016 and 2021, his most popular works were:
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (852 citations)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (327 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Oncology, Cancer research, Sarcoma and GiST are his primary areas of study.
His Internal medicine study typically links adjacent topics like Surgery.
His work deals with themes such as Adverse effect, Dacarbazine and Clinical trial, Phases of clinical research, which intersect with Oncology.
His Cancer research study combines topics in areas such as Soft tissue sarcoma, Gene and Drug resistance.
George D. Demetri has included themes like Enhancer, Imatinib, Epigenetics and Stromal tumor in his GiST study.
George D. Demetri combines subjects such as Sunitinib, Tyrosine kinase and Regorafenib with his study of Imatinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
